



Zika Virus and Immune Response

Guest Editors:

Dr. Nicholas Eyre

College of Medicine & Public
Health, Flinders University,
Bedford Park, SA 5042, Australia

Dr. Natalie Prow

Clinical & Health Sciences,
University of South Australia,
Adelaide, SA 5001, Australia

Deadline for manuscript
submissions:

closed (15 February 2021)

Message from the Guest Editors

Dear Colleagues,

The recent explosive outbreak of Zika virus (ZIKV) in the Americas in 2015-2016 revealed the unexpected association of ZIKV infection with serious neurodevelopmental disorders in unborn infants, now collectively known as ZIKV congenital syndrome (ZCS). For this Special Issue we encourage the submission of manuscripts addressing both innate and cellular immune responses towards ZIKV and mechanisms employed by the virus to evade these immune responses. We also encourage manuscripts addressing translational efforts towards development and testing of prophylactic vaccines and immunotherapeutics against ZIKV. Ultimately, an improved understanding of immune responses towards ZIKV and exploitation of this understanding will enable development of urgently required prophylactic and therapeutic interventions that are targeted towards ZIKV.

Dr. Nicholas Eyre

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com